Catalyst Pharmaceuticals, Inc. (CPRX)

4.0000 +0.1100 (+2.83%) At close: 4:00PM EST

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States
305 420 3200
http://www.catalystpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 76

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Patrick J. McEnany	Co-Founder, Chairman, Pres & CEO	908.7k	N/A	1947
Dr. Steven R. Miller	COO & Chief Scientific Officer	643.31k	N/A	1962
Dr. Gary Ingenito	Chief Medical & Regulatory Officer	646.75k	N/A	1956
Ms. Alicia Grande	VP, Treasurer & CFO	N/A	N/A	1971
Mr. Brian Elsbernd J.D.	Chief Legal & Compliance Officer	N/A	N/A	1964
Mr. Pete Curry Sr.	VP of Sales	N/A	N/A	N/A
Mr. Jeffrey Del Carmen	Chief Commercial Officer	N/A	N/A	1970
Mr. Philip B. Schwartz	Corp. Sec.	N/A	N/A	1955
Dr. Charles W. Gorodetzky	Consultant	N/A	N/A	1938

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.